CDK4/6抑制剂联合内分泌治疗晚期乳腺癌

doi:10.11904/j.issn.1002-3070.2021.03.018

实用肿瘤学杂志 ›› 2021, Vol. 35 ›› Issue (3): 287-290.doi: 10.11904/j.issn.1002-3070.2021.03.018

• 综述 • 上一篇

CDK4/6抑制剂联合内分泌治疗晚期乳腺癌

提谦综述, 张清媛审校

哈尔滨医科大学附属肿瘤医院血液淋巴瘤科(哈尔滨 150081)

收稿日期:2020-08-23 修回日期:2020-10-19 出版日期:2021-06-28 发布日期:2021-06-22
通讯作者: 张清媛,E-mail:13313612989@163.com
作者简介:提谦,女,(1994-),硕士研究生,从事乳腺癌内分泌耐药方面的研究。

Research progress of CDK4/6 inhibitors combined with endocrine therapy for advanced breast cancer

TI Qian, ZHANG Qingyuan

Department of Hematologic Lymphoma,Harbin Medical University Cancer Hospital,Harbin 150081,China

Received:2020-08-23 Revised:2020-10-19 Online:2021-06-28 Published:2021-06-22

摘要/Abstract

摘要： 内分泌治疗因疗效显著并具有安全性,是激素受体阳性(HR+)晚期乳腺癌患者的主要治疗方法。近年来内分泌领域发展迅速,如何延迟或逆转内分泌耐药及内分泌治疗新药物成为临床研究关注的焦点。研究发现,内分泌治疗耐药可能与CDK-RB-E2F通路有关,针对该通路的细胞周期蛋白依赖性激酶(CDK)4/6抑制剂可显著延缓HR+晚期乳腺癌患者内分泌耐药。CDK4/6抑制剂与内分泌药物联合使用,可提高HR+晚期乳腺癌患者的治疗客观缓解率,并可显著改善无进展生存期(PFS)。现就CDK4/6抑制剂的作用机制、药物有效性和安全性及相关临床试验做一综述。

关键词: 晚期乳腺癌, CDK4/6抑制剂, 内分泌治疗, 细胞周期

Abstract: Endocrine therapy is the main treatment method for patients with hormone receptor positive(HR+)advanced breast cancer due to its remarkable curative effect and safety.In recent years,the field of endocrinology has developed rapidly.How to delay or reverse endocrine resistance and new endocrine therapy drugs have become the focus of clinical research.Studies have found that endocrine therapy resistance may be related to the CDK-RB-E2F pathway.It has been found that endocrine therapy resistance may be related to the CDK-RB-E2F pathway.Cyclin-dependent kinase(CDK)4/6 inhibitors targeting this pathway can significantly delay endocrine resistance in patients with HR+ advanced breast cancer.The combined use of CDK4/6 inhibitors and endocrine drugs can improve the objective response rate of patients with HR+ advanced breast cancer,and can significantly improve progression-free survival(PFS).This article reviews the mechanism of action,drug effectiveness and safety of CDK4/6 inhibitors,and related clinical trials.

Key words: Advanced breast cancer, CDK4/6 inhibitor, Endocrine therapy, Cell cycle

中图分类号:

R737.9

提谦, 张清媛. CDK4/6抑制剂联合内分泌治疗晚期乳腺癌[J]. 实用肿瘤学杂志, 2021, 35(3): 287-290.

TI Qian, ZHANG Qingyuan. Research progress of CDK4/6 inhibitors combined with endocrine therapy for advanced breast cancer[J]. Journal of Practical Oncology, 2021, 35(3): 287-290.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/10.11904/j.issn.1002-3070.2021.03.018

http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/Y2021/V35/I3/287

参考文献

1 桂欣钰.CDK4/6抑制剂在激素受体阳性进展期乳腺癌治疗中的研究进展[J].中国肿瘤临床,2020,47(6):314-317.
2 Choo JR,Lee SC.CDK4-6 inhibitors in breast cancer:current status and future development[J].Expert Opin Drug Metab Toxicol,2018,14(11):1123-1138.
3 刘尔钰,杨昊,梁国华,等.CDK4/6 抑制剂联合 mTOR抑制剂在乳腺癌中的作用机制[J].实用肿瘤学杂志,2019,33(5):476-480.
4 Sini V,Cinieri S,Conte P,et al.Eendocrine therapy in post-menopausal women with metastatic breast cancer:from literature and guidelines to clinical practice[J].Crit Rev Oncol Hematol,2016,100:57-68.
5 李田宏,郭放谢晓东.2018年ASCO年会CDK4/6抑制剂联合内分泌治疗晚期乳腺癌最新进展解读[J].中外内分泌外科杂志,2019,13(2):159-161.
6 石磊,陈占红,王晓稼.2018年美国ASCO年会晚期乳腺癌内分泌治疗进展[J].中国肿瘤临床,2018,45(18);919-921.
7 周雅洁.CDK4/6抑制剂帕博西尼的研究进展[J].同济大学学报(医学版),2020,41(2):259-263.
8 De Luca A,Maiello MR,D′Alessio A,et al.Pharmacokinetic drug evaluation of palbociclib for the treatment of breast cancer[J].Expert Opin Drug Metab Toxicol,2018,14(9):891-900.
9 Finn RS,Boer K,Bondarenko I,et al.Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2-advanced breast cancer(PALOMA-1,TRIO-18)[J].Breast Cancer Res Treat,2020,183(2):419-428.
10 Rugo HS,Finn RS,Diéras V,et al.Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor2-negative advanced breast cancer with extended follow-up[J].Breast Cancer Res Treat,2019,174(3):719-729.
11 Cristofanilli M,DeMichele A,Giorgetti C,et al.Predictors of prolonged benefit from palbociclib plus fulvestrant in women with endocrine-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in PALOMA-3[J].Eur J Cancer,2018,104:21-31.
12 Masuda N,Inoue K,Nakamura R,et al.Palbociclib in combination with fulvestrant in patients with hormone receptor-positive,human epidermal growth factor receptor 2-negative advanced breast cancer:PALOMA-3 subgroup analysis of Japanese patients[J].Int J Clin Oncol,2019,24(3):262-273.
13 Rascon K,Flajc G,De Angelis C,et al.Ribociclib in HR+/HER2-advanced or metastatic breast cancer patients[J].Ann Pharmacother,2019,53(5):501-509.
14 Hortobagyi GN,Stemmer SM,Burris HA,et al.Updated results from MONALEESA-2,a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive,HER2-negative advanced breast cancer[J].Ann Oncol,2018,29(7):1541-1547.
15 Tripathy D,Im SA,Colleoni M,et al.Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive,advanced breast cancer(MONALEESA-7):a randomised phase 3 trial[J].Lancet Oncol,2018,19(7):904-915.
16 Slamon DJ,Neven P,Chia S,et al.Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive,human epidermal growth factor receptor 2-negative advanced breast cancer:MONALEESA-3[J].J Clin Oncol,2018,26(24):2465-2472.
17 Kotake T,Toi M.Abemaciclib for the treatment of breast cancer[J].Expert Opin Pharmacother,2018,19(5):517-524.
18 Dickler MN,Tolaney SM,Rugo HS,et al.MONARCH 1,A phase II study of abemaciclib,a CDK4 and CDK6 inhibitor,as a single agent,in patients with refractory HR(+)/HER2(-)metastatic breast cancer[J].Clin Cancer Res,2017,23(17):5218-5224.
19 Sledge GW Jr,Toi M,Neven P,et al.The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive,ERBB2-negative breast cancer that progressed on,endocrine therapy-MONARCH2:a randomized clinical trial[J].JAMA Oncol,2019,6(1):116-24.
20 Johnston S,Martin M,Di Leo A,et al.MONARCH 3 final PFS:a randomized study of abemaciclib as initial therapy for advanced breast cancer[J].NPJ Breast Cancer,2019,5:5.
21 Goetz MP,Toi M,Campone M,et al.MONARCH 3:abemaciclib as initial therapy for advanced breast cancer[J].J Clin Oncol,2017,35(32):3638-3646.

[1]	刘尔钰, 杨昊, 梁国华, 赵晏方, 赵文辉. CDK4/6抑制剂联合mTOR抑制剂在乳腺癌中的作用机制[J]. 实用肿瘤学杂志, 2019, 33(5): 476-480.
[2]	白晓斌, 霍龙伟, 谢万福, 徐高峰, 王茂德. Chk1在胶质母细胞瘤中的表达及其与肿瘤生物学行为和预后生存的关联性[J]. 实用肿瘤学杂志, 2019, 33(2): 122-127.
[3]	候聪芳综述, 达林泰审校. RbAP48与恶性肿瘤的研究进展[J]. 实用肿瘤学杂志, 2018, 32(5): 445-449.
[4]	林荣杰, 尹航, 周云峰. ON123300对ER阳性人乳腺癌MCF-7细胞的影响及机制研究[J]. 实用肿瘤学杂志, 2018, 32(3): 193-197.
[5]	石磊(综述), 许培权(审校). 绝经前激素受体阳性乳腺癌内分泌治疗现状[J]. 实用肿瘤学杂志, 2017, 31(2): 170-174.
[6]	刘跃欣, 周琪, 闫金银综述, 胡万宁审校. 蒜素抗肿瘤的研究进展[J]. 实用肿瘤学杂志, 2014, 28(6): 557-560.
[7]	姚志峰, 姚建新, 徐国平, 刘永彪. 西妥昔单抗对肺腺癌A549细胞株辐射增敏作用的研究[J]. 实用肿瘤学杂志, 2013, 27(1): 11-16.
[8]	栾天, 佟雷, 徐威, 钟照华. MiR-122促进原发性肝细胞癌Huh-7细胞凋亡[J]. 实用肿瘤学杂志, 2012, 26(5): 428-431.
[9]	罗敏, 顾琳慧, 冯建国, 林能明, 苏丹, 徐海燕, 许雅思. 重楼皂苷Ⅰ作用于人卵巢癌细胞株体外生物学效应研究[J]. 实用肿瘤学杂志, 2012, 26(4): 293-297.
[10]	徐向英, 许德权, 陈蜜, 赵芳宗, 胡松柳, 徐建宇. Bcl-2基因表达抑制联合射线对NCI-H460细胞增殖状态及细胞周期影响的研究[J]. 实用肿瘤学杂志, 2012, 26(1): 37-41.
[11]	莫雪莉, 王德林, 曹玉娟, 杜芳, 曹凤, 孙建华, 刘承伟, 郝龙英. 紫杉醇周疗同步放疗治疗复发转移乳腺癌[J]. 实用肿瘤学杂志, 2011, 25(5): 437-438.
[12]	宋三泰, 张少华. 乳腺癌内分泌治疗的基本药物和新动向[J]. 实用肿瘤学杂志, 2010, 24(4): 301-304.
[13]	张瑾, 张霄蓓. 唑来膦酸在乳腺癌辅助治疗领域的临床研究进展[J]. 实用肿瘤学杂志, 2010, 24(4): 305-307.
[14]	吴炅, 陈嘉健. 早期绝经前乳腺癌辅助内分泌治疗策略[J]. 实用肿瘤学杂志, 2010, 24(4): 311-313.
[15]	徐晓颖, 李秀荣, 李娜, 雷宏伟, 苏旭, 李国权. siRNA抑制survivin基因表达对HeLa细胞周期的影响[J]. 实用肿瘤学杂志, 2010, 24(4): 368-372.

CDK4/6抑制剂联合内分泌治疗晚期乳腺癌

Research progress of CDK4/6 inhibitors combined with endocrine therapy for advanced breast cancer

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价